View in EDS

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study.

Saved in:
Bibliographic Details
Title: Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study.
Authors: Liao PW; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Life Science, Tunghai University, Taichung, Taiwan., Ko BS; School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei City, Taiwan.; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan., Su YC; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Nursing, Taichung Veterans General Hospital, Taichung, Taiwan., Chao WT; Department of Life Science, Tunghai University, Taichung, Taiwan., Teng CJ; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Life Science, Tunghai University, Taichung, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Source: Cancer medicine [Cancer Med] 2026 Jun; Vol. 15 (6), pp. e72022.
Publication Type: Journal Article; Comparative Study
Journal Info: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42244155
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Liao+PW%22">Liao PW</searchLink>; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Life Science, Tunghai University, Taichung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Ko+BS%22">Ko BS</searchLink>; School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei City, Taiwan.; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.<br /><searchLink fieldCode="AU" term="%22Su+YC%22">Su YC</searchLink>; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Nursing, Taichung Veterans General Hospital, Taichung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chao+WT%22">Chao WT</searchLink>; Department of Life Science, Tunghai University, Taichung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Teng+CJ%22">Teng CJ</searchLink>; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Life Science, Tunghai University, Taichung, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101595310%22">Cancer medicine</searchLink> [Cancer Med] 2026 Jun; Vol. 15 (6), pp. e72022.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Comparative Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22John+Wiley+%26+Sons+Ltd%22">John Wiley & Sons Ltd </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101595310 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2045-7634 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220457634%22">20457634 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42244155
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cam4.72022
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e72022
    Titles:
      – TitleFull: Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Liao PW
      – PersonEntity:
          Name:
            NameFull: Ko BS
      – PersonEntity:
          Name:
            NameFull: Su YC
      – PersonEntity:
          Name:
            NameFull: Chao WT
      – PersonEntity:
          Name:
            NameFull: Teng CJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2026 Jun
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2045-7634
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Cancer medicine
              Type: main
ResultId 1